A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain

Acta Clinica Belgica

Volumn 63, Issue 3, 2008, Pages 170-178

  Annemans, Lieven ^a,b,f   Caekelbergh, K ^a   Morlion, B ^c   Hans, G ^d   De Cock, P ^e   Marbaix, S ^e  

^a IQVIA   (United States)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e PFIZER INC   (United States)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cost utility; Markov; Neuropathic pain; Pregabalin

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PLACEBO; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; COST CONTROL; COST UTILITY ANALYSIS; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE TITRATION; DRUG USE; DRUG WITHDRAWAL; EVOLUTION; FEMALE; HEALTH CARE; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; NEUROPATHIC PAIN; OBSERVATIONAL STUDY; PATIENT CARE; PATIENT COMPLIANCE; POPULATION; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SHORT FORM 36; SIMULATION; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT;

EID: 47949111253     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2008.027     Document Type: Article

References (23)

1. Stacey BR. Management of peripheral neuropathic pain. Am J Phys Med Rehabil 2005 Mar; 84(3 Suppl):S4-S16.
2. MacFarlane BV, Wright A, O'Callaghan J, Benson HA. Chronic neuropathic pain and its control by drugs. Pharmacol Therap 1997; 75: 1-19.
3. Karlsten R, Gordh T. How do drugs relieve neurogenic pain? Drugs Aging 1997 Nov; 11(5):398-412.
4. Bowsher D. Neurogenic pain syndromes and their management. Br Med Bull 1991 Jul; 47(3):644-66.
5. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006 Feb; 10(2):127-35.
6. Backonja MM. Gabapentin Monotherapy for the Symptomatic Treatment of Painful Neuropathy: A multicenter, Double-blind, placebo-controlled Trial in patients with diabetes mellitus. Epilepsia 1999; 40 (Suppl.6): S557-S59.
7. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004 Sep; 21(9):976-82.
8. Johnson R. Herpes Zoster- Predicting and minimizing the impact of post-herpetic neuralgia. J Antimicrob Chemother 2001; 47: 1-8.
9. Attal N, Cruccu G, Haanpaa M, et al. EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006 Nov; 13(11):1153-69.
10. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005 Apr; 6(4):253-60.
11. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004 Dec 14; 63(11):2104-10.
12. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004 Aug; 110(3):628-38.
13. van Seventer R, Feister HA, Young JP Jr, Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006 Feb; 22(2):375-84.
14. Sabatowski R, Galvez R, Cherry DA, et al. 1008-045 Study Group. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004 May; 109(1-2):26-35.
15. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003 Apr 22; 60(8):1274-83.
16. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005 Jun; 115(3):254-63.
17. Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK. Pregabalin in central neuropathic pain associated with spinal cord injury. Neurology 2006; 67:1792-800.
18. EMEA: European Medicines Agency. Evaluation of Medicines for Human Use. Committee for medicinal products for human use (CHMP) Guideline on clinical investigation of medicinal products intended for the treatment of neuropathic pain. November 2004.
19. Drummond M, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes, 2005. Oxford University Press.
20. Annemans L, Van Campenhout H, Maeyaert J, Morlion B. Prospective assessment of the health and economic burden of neuropathic pain. Value in Health 2004; 7 (6): 726.
21. Thompson D. Toward a Pharmacoeconomic Model of Neuropathic Pain. The Clin J Pain 2002; 18:366-72.
22. Brazier J, Roberts J, Deverill H. The estimation of a preference-based measure of health from the SF-36. J Health Economics 2002; 21(2):271-92.
23. IFEB Belgisch Instituut voor Farmaceutische Epidemiologie. Report on the use of reimbursed drugs for neuropathic pain; 2006.